Pharmaceuticals

Roche Holdings Ltd. (RHHBY) recently announced that the US Food and Drug Administration (FDA) approved Actemra (tocilizumab) to be used for slowing structural joint damage, improving physical function, and achieving major clinical response in adult patients with moderately to severely active...

Shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) are lower on the session by 0.15%, currently trading at $19.80. The stock has been moving largely higher over the past six months is currently trading above the 200-day moving average. Options traders are buying calls on the name today. Though action...

Valeant Pharmaceuticals Int (USA) (NYSE: VRX) is skyrocketing on the back of the company raising its guidance at a conference call. The company said it now sees earnings of 44-48 cents, versus estimates of 45 cents. It also said it sees revenues of $51-$520 million versus estimates of $502.7...

Shares of Valeant Pharmaceuticals (NYSE: VRX) are shooting higher today, currently higher by 14.99%, trading at $34.44. Shares are on the move following commentary from the company regarding 2011 guidance. VRX management said that it sees FY 2011 earnings per share of $2.25 to $2.50 on revenues of...

By 11:08 am, the Dow Jones Industrial Average was down 53.84 points, or 0.46%, to 11,669.05, while the broader Standard & Poor's 500 index had lost 6.03 points, or 0.47%. The NASDAQ composite index fell 3.73 points, or 0.14%. Some of the narrow based indexes that are still afloat in the markets...

Goldman Sachs is holding its Healthcare CEO's Conference today, and Bristol-Myers (NYSE: BMY), Merck (NYSE: MRK) and Celgene (NASDAQ: CELG) are expected to attend. Shares of Merck and Celgene are higher on the day, while Bristol-Myers is lower in line with the broader market.

At 10:25 am, the Dow gained 0.01% to 11,723.99, the broader Standard & Poor's 500 index moved down 0.03% to 1,276.22 and the NASDAQ composite index rose 0.21% to 2,707.84. The industries that are supporting the market today are: Consumer Services: This industry jumped 2.28% by 10:25 am. The top...

Recently, Germany's Bayer (BAYRY) filed an application with the European Medicines Agency (EMA), seeking approval from the European regulatory body to market  its blood thinner Xarelto (rivaroxaban) in Europe. Clearance has been sought to market the drug, co-developed with Johnson & Johnson (...

Recently, Germany's Bayer (BAYRY) filed an application with the European Medicines Agency (EMA), seeking approval from the European regulatory body to market  its blood thinner Xarelto (rivaroxaban) in Europe. Clearance has been sought to market the drug, co-developed with Johnson & Johnson (...

RBC Capital upgrades the following companies: EV Energy (NASDAQ: EVEP) from Sector Perform to Outperform. Price target increased from $37 to $45. Elan (NYSE: ELN) from Underperform to Sector Perform. Price target increased from $4 to $8.

Teva Pharmaceutical Industries Ltd. (TEVA) recently completed the acquisition of Theramex, a Europe-based women's health business with a presence in several countries. Teva had initially announced its intention to acquire Theramex in late October 2010 at which time the company entered into a...

Santarus, Inc. (SNTS) and Depomed, Inc. (DEPO) recently announced that they have resumed supply of their type II diabetes product, Glumetza 500 mg. Product Recalled in June 2010 In June 2010, Depomed had announced a voluntary recall of 52 lots due to the presence of certain substance in...

Santarus, Inc. (SNTS) and Depomed, Inc. (DEPO) recently announced that they have resumed supply of their type II diabetes product, Glumetza 500 mg. Product Recalled in June 2010 In June 2010, Depomed had announced a voluntary recall of 52 lots due to the presence of certain substance in...

Amarin Corporation plc (Nasdaq: AMRN) today announced the pricing of an underwritten public offering of 12,000,000 American Depositary Shares at a price to the public of $7.60 per ADS. The net proceeds to the Company from this offering are expected to be approximately $87.1 million, after...

Teva Pharmaceutical Industries Ltd. (TEVA) recently completed the acquisition of Theramex, a Europe-based women's health business with a presence in several countries. Teva had initially announced its intention to acquire Theramex in late October 2010 at which time the company entered into a...